Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 7/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CLK1 | P49759 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 8/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.41 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.40 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | CLK2 | P49760 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.40 |
| ▸ | RAF1 | P04049 | 4/20 | 0.40 |
| ▸ | BRAF | P15056 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1891436 | 0.95 | PIK3CA (0.47) | PIK3CANPC1ALDH1A1TSHRCLK1 | |
| SCHEMBL3838017 | 0.94 | NPC1 (0.45) | PIK3CANPC1ALDH1A1TSHRCLK1 | |
| SCHEMBL12991910 | 0.80 | PIK3CG (0.50) | PIK3CANPC1ALDH1A1RAB9APIK3CD | |
| SCHEMBL1888686 | 0.80 | PIK3CG (0.60) | PIK3CANPC1ALDH1A1TSHRCLK1 | |
| SCHEMBL1883394 | 0.74 | PIK3CG (0.54) | PIK3CAALDH1A1PIK3CDPIK3CGPIK3CB | |
| SCHEMBL5048755 | 0.74 | NPC1 (0.51) | PIK3CANPC1ALDH1A1TSHRCLK1 | |
| SCHEMBL1892392 | 0.73 | PIK3CA (0.49) | PIK3CANPC1ALDH1A1RAB9APIK3CD | |
| SCHEMBL48730 | 0.73 | PIK3CD (0.74) | PIK3CAALDH1A1CLK1PIK3CDPIK3CG | |
| SCHEMBL2832443 | 0.72 | PIK3CG (0.48) | PIK3CDPIK3CGPI4KB | |
| SCHEMBL49235 | 0.71 | PIK3CD (0.65) | PIK3CAALDH1A1CLK1PIK3CDPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2157091-B1 | Inhibitors of phosphatidylinositol 3-kinase | NOVARTIS AG (CH) | 2015-06-10 | — | — | EP | disclosed |
| US-20130172349-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | NOVARTIS AG (CH) | 2013-07-04 | — | — | US | disclosed |
| US-8404684-B2 | Inhibitors of phosphatidylinositol 3-kinase | NOVARTIS AG (CH) | 2013-03-26 | — | — | US | disclosed |
| US-20110105535-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | NOVARTIS AG | 2011-05-05 | — | — | US | disclosed |
| EP-2157091-A1 | Inhibitors of phosphatidylinositol 3-kinase | Novartis AG (CH) | 2010-02-24 | — | — | EP | disclosed |
| EP-1622897-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | Novartis AG (CH) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004096797-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | NOVARTIS AG (CH) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105535-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CA, PIK3CD, PIP4K2C | PIK3CA 1/4885NPC1 1578/4885ALDH1A1 4151/4885 |
| US-20130172349-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CA, PIK3CD, PIP4K2C | PIK3CA 1/4885NPC1 1578/4885ALDH1A1 4151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.